ATC/DDD classification

(1)

ATC/DDD classification

The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/

DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information.

ATC/DDD classification (temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2018.

Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2019. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2020 version of the ATC/DDD Index.

New ATC 5^thlevel codes

ATC level name/INN ATC code

acalabrutinib L01XE51

amenamevir J05AX26

amlodipine and celecoxib C08CA51

arginine and lysine V03AF11

atorvastatin and omega-3 fatty acids C10BA08

baloxavir marboxil J05AX25

betrixaban B01AF04

brolucizumab S01LA06

cemiplimab L01XC33

crizanlizumab B06AX01

daclatasvir, asunaprevir and beclabuvir J05AP58

darolutamide L02BB06

elagolix H01CC03

elbasvir J05AP10

entinostat L01XX64

(2)

New ATC 5th level codes (continued)

enviomycin J04AB06

esketamine N06AX27¹⁾

favipiravir J05AX27

ferrous sodium citrate B03AA12

fimasartan and amlodipine C09DB09

fremanezumab N02CX09

gilteritinib L01XE54

glasdegib L01XX63

glycopyrronium D11AA01

grazoprevir J05AP11

imlifidase L04AA41

inotersen N07XX15

irbesartan, amlodipine and hydrochlorothiazide C09DX07

ivosidenib L01XX62

lamivudine and dolutegravir J05AR25

laninamivir J05AH04

larotrectinib L01XE53

latanoprost and netarsudil S01EE51

latanoprostene bunod S01EE06

luspatercept B03XA06

methionine (¹¹C) V09IX13

mosapride A03FA09

moxidectin P02CX03

opinercept L04AB07

pegvaliase A16AB19

perindopril, bisoprolol and amlodipine C09BX04

plazomicin J01GB14

quizartinib L01XE52

rabeprazole, amoxicillin and clarithromycin A02BD12

Continued

552

(3)

New ATC 5th level codes (continued)

rabeprazole, amoxicillin and metronidazole A02BD13

ravulizumab L04AA43

rifamycin A07AA13

risankizumab L04AC18

rosuvastatin and fimasartan C10BX16

rosuvastatin and omega-3 fatty acids C10BA07

siponimod L04AA42

solriamfetol N06BA14

sotagliflozin A10BK06

tafenoquine P01BA07

tamsulosin and tadalafil G04CA54

tecovirimat J05AX24

ulinastatin B02AB05

vancomycin S01AA28

vonoprazan, amoxicillin and clarithromycin A02BD14

vonoprazan, amoxicillin and metronidazole A02BD15

1Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14

(4)

554

New ATC level codes (other than 5th levels):

Other hematological agents B06AX

Changes of ATC level names

Previous New ATC code

lactobacillus fermentum lactobacillus G01AX14

microspheres of human

albumin perflutren, human albumin microspheres V08DA01 microspheres of

phospholipids perflutren, phospholipid microspheres V08DA04 perflubutane polymer

microspheres perflubutane, phospholipid microspheres V08DA06 sulfur hexafluoride sulfur hexafluoride, phospholipid

microspheres V08DA05

New DDDs

ATC level name/INN DDD unit Adm.R* ATC code

amenamevir 0.4 g O J05AX26

apalutamide 0.24 g O L02BB05

asunaprevir 0.2 g O J05AP06

brodalumab 15 mg P L04AC12

calcium aminosalicylate 15 g O J04AA03

cerliponase alfa 21 mg P A16AB17

elbasvir 50 mg O J05AP10

enviomycin 1 g P J04AB06

erenumab 2.5 mg P N02CX07

favipiravir 1.6 g O J05AX27

glycerol phenylbutyrate 15 g O A16AX09

grazoprevir 0.1 g O J05AP11

laninamivir 40 mg Inhal.powder J05AH04

levofloxacin 0.24 g Inhal.solution J01MA12

nabilone 3 mg O A04AD11

Continued

(5)

New DDDs (continued)

opinercept 7 mg P L04AB07

pentosan polysulfate sodium 0.3 g O G04BX15

peramivir 0.6 g P J05AH03

pridinol 6 mg O M03BX03

semaglutide 0.11 mg P A10BJ06

sodium zirconium cyclosilicate 7.5 g O V03AE10

vidarabine 0.7 g P J05AB03

Changes of DDDs

ATC level name/INN Previous DDD New DDD ATC code

liraglutide 1.2 mg P 1.5 mg P A10BJ02

(6)

556

ATC/DDD classification (final)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in March 2018.

These are considered as final and will be included in the January 2019 version of the ATC/DDD Index.

New ATC 5^thlevel codes

abemaciclib L01XE50

angiotensin II C01CX09

apalutamide L02BB05

avatrombopag B02BX08

candesartan, amlodipine and hydrochlorothiazide C09DX06

cannabidiol N03AX24

cefpodoxime and beta-lactamase inhibitor J01DD64

copanlisib L01XX61

doravirine J05AG06

edaravone N07XX14

fexinidazole P01CA03

fostamatinib B02BX09

gemigliptin and rosuvastatin A10BH52

hydrogen peroxide D11AX25

ibalizumab J05AX23

lamivudine, tenofovir disoproxil and doravirine J05AR24

leuprorelin and bicalutamide L02AE51

metformin, saxagliptin and dapagliflozin A10BD25

omidenepag S01EX06

prasterone G03XX01

talazoparib L01XX60

telotristat A16AX15

trifarotene D10AD06

(7)

New ATC level codes (other than 5th levels):

Other sex hormones and modulators of the genital system G03XX

Change of ATC codes:

ATC level name/INN Previous ATC New ATC

dimethyl fumarate N07XX09 L04AX07

Changes of ATC level names

Previous New ATC code

Angiotensin II antagonists,

plain Angiotensin II receptor blockers (ARBs),

plain C09C

plain Angiotensin II receptor blockers (ARBs),

plain C09CA

combinations Angiotensin II receptor blockers (ARBs),

combinations C09D

Angiotensin II antagonists and

diuretics Angiotensin II receptor blockers (ARBs)

and diuretics C09DA

Angiotensin II antagonists and

calcium channel blockers Angiotensin II receptor blockers (ARBs)

and calcium channel blockers C09DB Angiotensin II antagonists,

other combinations Angiotensin II receptor blockers (ARBs),

other combinations C09DX

combinations potassium (different salts in combination) A12BA30 fluoromethylcholine (¹⁸F) fluorocholine (¹⁸F) V09IX07

(8)

558

New DDDs

artemether 0.28 g R P01BE02

artesunate 0.28 g R P01BE03

benralizumab 0.54 mg P R03DX10

chenodeoxycholic acid 1 g O A05AA01

cladribine 0.34 mg O L04AA40

dupilumab 21.4 mg P D11AH05

emicizumab 15 mg P B02BX06

ertugliflozin 10 mg O A10BK04

guselkumab 1.79 mg P L04AC16

letermovir 0.48 g O,P J05AX18

ocrelizumab 3.29 mg P L04AA36

patiromer calcium 8.4 g O V03AE09

rolapitant 0.18 g O A04AD14

telotristat 0.75 g O A16AX15

* Administration Route: O = oral; P= parenteral.

Change of DDD

ATC level name/INN Previous DDD New DDD ATC code

aprepitant 95 mg O 165 mg O A04AD12

aprepitant¹ 95 mg P 150 mg P A04AD12

temocillin 2 g P 4 g P J01CA17

vasopressin

(argipressin) 4 U P 40 U P H01BA01

1refers to fosaprepitant

WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018

***